transmembrane protein 150BGenealiases: DRAM3 · TMEM224 · TTN2
Q-omics provides the consensus-scored TMEM150B profile across patient tissues and cancer cell-line models. TMEM150B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM150B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TMEM150B RNA expression shows 21,481 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where TMEM150B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM150B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM150B survival associations across molecular data types. TMEM150B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM150B RNA expression–survival associations across cancer types. High TMEM150B expression shows unfavorable associations in UVM, KIRC and THYM, but favorable associations in HNSC, SKCM and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM150B RNA expression.
This table summarizes TMEM150B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM150B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM150B shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, THCA, LIHC and STAD. The HNSC box plot shows higher TMEM150B RNA expression in tumor versus normal tissue (log2 FC = +0.886, t-test p < 0.001).
This table shows molecular features associated with TMEM150B in patient tissues and cancer cell lines. In patient samples, TMEM150B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM150B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
